SCHEMBL3635128

SCHEMBL3635128

CN1CCN(C(C(=O)O)c2ccc3c(c2)OCCO3)CC1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.57
PTGS2 P35354 1/20 0.57
HPGD P15428 2/20 0.51
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
OGA O60502 2/20 0.48
TP53 P04637 1/20 0.47
HTT P42858 4/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.45
LMNA P02545 2/20 0.45
TSHR P16473 1/20 0.45
USP2 O75604 1/20 0.44
GAA P10253 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635007 0.92 TP53 (0.55) ALDH1A1OGATP53HTTKDM4E
SCHEMBL3640505 0.87 HDAC3 (0.50) PTGS1PTGS2HPGDALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL3639643 0.80 OGA (0.45) ALDH1A1OGATP53KDM4EMAPT
SCHEMBL3640126 0.76 TP53 (0.52) ALDH1A1TP53HTTKDM4EMAPT
SCHEMBL3746159 0.76 ALDH1A1 (0.46) PTGS1PTGS2HPGDALDH1A1SMN1; SMN2
SCHEMBL3636800 0.76 GHSR (0.61) HPGDALDH1A1SMN1; SMN2OGATP53
SCHEMBL19283564 0.76 OGA (0.61) PTGS1PTGS2OGA
SCHEMBL3728026 0.76 LMNA (0.40) ALDH1A1TP53KDM4EMAPTLMNA
SCHEMBL13044326 0.75 HPGD (0.50) HPGDLMNATSHRGAA
SCHEMBL13044353 0.75 LMNA (0.39) HPGDALDH1A1SMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R PTGS1 1475/4885PTGS2 2215/4885HPGD 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.